Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Baldwin, one of the Senate’s most liberal members, beat Vukmir, a staunch supporter of President Donald Trump, by double digits, based on unofficial results. Baldwin won a number of counties that Trump took in 2016 when he narrowly carried Wisconsin by less than 1 point. Baldwin said in her victory speech Tuesday that her win sends a “loud and clear message” that people in Wisconsin want a senator who will stand up for them against special interests. Baldwin was an early target for outside conservative groups that spent millions attacking her over the summer. But Baldwin outraised Vukmir 5-to-1 and blanketed the airwaves with ads contrasting her support for the Affordable Care Act with votes Vukmir made in the state Legislature in favor of insurance companies. “Democrats, Republicans and independents sent a loud and clear message tonight that they wanted a senator who works not for the special interests, but someone who works for you,” Baldwin said in her victory speech. Vukmir campaigned as the underdog and urged Republicans who supported Trump to surprise the pollsters like they did in 2016. But Democrats came through for Baldwin in a race that marked the first time in Wisconsin history both major party candidates for U.S. Senate were women. Baldwin had recent history on her side: In the last three midterm elections, no incumbent Wisconsin senator from the party not in the White House lost a re-election bid. Baldwin, 56, won her first local race at age 24 and was elected to the Senate in 2012, beating former Republican Gov. Tommy Thompson, in a year when former President Barack Obama was also on the ballot. Baldwin was the first openly gay person elected to the Senate. Baldwin and Vukmir disagreed on every major issue including health care, immigration, taxes, abortion, national security, gun control and criminal justice. Stephenie Hamen, a 42-year-old artist from Sun Prairie, said she voted for Baldwin, in part as a vote for women’s rights and a vote against Trump. “I don’t know if it was to vent (against the president),” she said. “It’s a way to stand up for women as Americans and be heard. It’s a scary time to be a woman in America. No matter what (Trump) says about being a white man in America, it’s scarier for women and minorities. If the Republicans stay in power, we’re writing a check for that party to do whatever they want. If we continue down that path we have no idea what’s coming next.” While Baldwin campaigned with former President Barack Obama and independent Vermont Sen. Bernie Sanders, Vukmir rallied with Trump and forcefully supported his Supreme Court pick Brett Kavanaugh. Baldwin voted against his confirmation. Baldwin is a supporter of Sanders’ “Medicare for All” bill and ran as a defender of the Affordable Care Act. Baldwin cast Vukmir, a nurse, as the potential deciding vote to repeal the law and its guarantees of insurance for people with pre-existing conditions. Vukmir, 60, focused on Baldwin’s handling of the opioid over-prescription crisis at the Tomah Veterans Affairs Medical Center, saying her inaction let veterans down. But the widow and parents of a veteran who died there has come out in support of Baldwin, cutting television ads to help her and undercutting Vukmir’s criticism. Baldwin recounted the story of her childhood illness that made her an advocate for universal health coverage, while also speaking in detail for the first time about her mother’s struggles with mental illness and prescription drug abuse. Baldwin said that has fueled her fight against opioid abuse. ___ Follow Scott Bauer on Twitter: https://twitter.com/sbauerAP ___ For AP’s complete coverage of the U.S. midterm elections: http://apne.ws/APPolitics
Example Output: Wisconsin Democratic Sen. Baldwin cruises to second term.

Example Input: The story makes clear the “big unknown” remains the price and “how much people are willing to spend to cut a day or so off of a bout of flu.” The story reports that Genentech, the drug’s manufacturer, said it’s too early to comment on the drug’s U.S. price. The story also notes that in Japan, where the drug was invented, it “sells for the equivalent of about $43.50.” The story uses terms like “a little more than a day” and “nearly a day” and “substantially” to describe the drug’s reduction in flu symptoms, fever, and coughing and sneezing, respectively. It does not explain, as the news release does, that: “Similar efficacy results were seen between baloxavir marboxil and [Tamiflu] in relation to duration of symptoms and fever reduction.” In other words, on the symptom front, both drugs were the same. According to the news release, a difference was seen in the length of time the virus was shed from the body (presumably through coughing and sneezing): 24 hours for baloxavir marboxil verses 72 hours for Tamiflu. The news release also states that there was also a difference seen in the level of virus in the nose and throat, but it provides no precise numbers. It is not known whether this benefit translates into less infection transmission, and the story should have made that clear. The news release issued by Genentech about the FDA’s decision to grant priority review describes baloxavir marboxil’s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu. The STAT News story does not mention any potential harms. This evidence comes from the randomized phase III Capstone-1 study the FDA will review, which included 1,436 people in the US and Japan. It excluded people older than 64. The news story does not note this exclusion, nor does it state a key problem with this study: It has never been published in a peer-reviewed journal (instead, a study abstract was released as part of ID Week 2017). This means the full data analysis has never been seen by anyone other than the researchers. We explained why this is important in February 2018, when we discussed news coverage of the drug’s approval in Japan. The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication. The article includes two sources: Mark Eisner, Genentech’s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization’s influenza collaborating center at St. Jude Children’s Research Hospital in Memphis. Eisner’s affiliation with Genentech, the drug’s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what–if anything–is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths. The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days. It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication. The story explains that it’s been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.) The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.
Example Output: A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S.

Example Input: Many of China’s usually teeming cities have almost become ghost towns during the past two weeks as Communist Party rulers ordered virtual lockdowns, canceled flights, closed factories and shut schools. Even on Monday, a large number of workplaces and schools will remain closed and many white-collar employees will work from home. The scale of the potential hit to an economy that has been the engine of global growth in recent years has taken a toll on financial markets, as shares slumped and investors switched into safe-havens such as gold, bonds and the Japanese yen. China’s ambassador to Britain described the newly identified virus as “the enemy of mankind” in a BBC interview on Sunday, but added it “is controllable, is preventable, is curable”. “At this moment is very difficult to predict when we are going to have an inflection point,” Liu Xiaoming said. “We certainly hope it will come soon, but the isolation and quarantine measures have been very effective.”  China’s cabinet said it would coordinate with transport authorities to ensure the smooth return to work of employees in key industries such as food and medicines. The State Council’s special coronavirus group also said workers should return in “batches”, rather than all at once, in order to reduce infection risks. China’s National Health Commission recorded another 89 deaths on Saturday, pushing the total well above the 774 who died from SARS, or Severe Acute Respiratory Syndrome in 2002/2003. GRAPHIC: Comparing new coronavirus to SARS and MERS - here  Total confirmed coronavirus cases in China stood at 37,198, commission data showed. New infections recorded the first drop below 3,000 cases Feb. 2, at 2,656 cases. Of those, 2,147 cases were in Hubei province, the epicenter of the outbreak. The virus has also spread to at least 27 countries and territories, according to a Reuters count based on official reports, infecting more than 330 people. Two deaths have been reported outside mainland China - both of Chinese nationals. The latest patients outside China include a group of British nationals staying in a mountain village in Haute-Savoie in the Alps, French health officials said, raising fears of further infections at a busy period in the ski season. A British man who contracted the virus while attending a conference in Singapore may have infected seven other people when he stopped off at a chalet in the French village on his way home, health experts said. Those infected include a British man diagnosed in Spain and a Briton found to have the disease in the UK, both of whom appeared to have been part of the chalet group. GRAPHIC: Tracking the novel coronavirus - here  As millions of Chinese prepared to go back to work, the public dismay and mistrust of official numbers was evident on Weibo, China’s equivalent of Twitter. “What’s even more frustrating is that these are only the ‘official’ data,” said one user. “We all know we can’t purchase masks anywhere, why are we still going back to work?” said a second. “More than 20,000 doctors and nurses around the country have been sent to Hubei, but why are the numbers still rising?” asked a third. Authorities had told businesses to tack up to 10 extra days on to holidays that had been due to finish at the end of January and some restrictions continued. Gaming giant Tencent Holdings said it had asked staff to continue working from home until Feb. 21. Hebei province, which surrounds Beijing, will keep schools shut until March 1, the People’s Daily newspaper said. Several provinces have shut schools until the end of February. The local government in the southern manufacturing hub of Shenzhen, meanwhile, denied a report in the Nikkei business daily that it had blocked a plan by Apple supplier Foxconn Technology Co to resume production in China from Monday. The company would restart once inspections were completed, it said. Among the latest deaths, 81 were in Hubei. An American hospitalized in the provincial capital Wuhan, where the outbreak began, became the first confirmed non-Chinese victim. Joseph Eisenberg, professor of epidemiology at the School of Public Health at the University of Michigan, said it was too early to say whether the epidemic was peaking. “Even if reported cases might be peaking, we don’t know what is happening with unreported cases,” he said. Major cities and capitals announced new travel restrictions as concern over the spread of the virus increased. Chinese-ruled Hong Kong introduced a two-week quarantine on Saturday for all people arriving from the mainland, or who have been there during the previous 14 days. Malaysia expanded its ban on visitors from China. France issued a new travel advisory for its citizens, saying it did not recommend traveling to China unless there was an “imperative” reason. Italy asked children traveling from China to stay away from school for two weeks voluntarily. Princess Cruises, operator of the Diamond Princess cruise ship quarantined off Japan, said a further six people had tested positive, bringing the total cases aboard to 70. (This story corrects to remove in paragraph 23 reference to 53-year-old geneticist who died, citing Washington Post, after newspaper said it incorrectly identified the name and age of a U.S. citizen who died.)
Example Output:
'Enemy of mankind': Coronavirus deaths top SARS as China returns to work.